MDGL vs. LRCX
MDGL (Madrigal Pharmaceuticals, Inc.) and LRCX (Lam Research Corporation) are both stocks. MDGL operates in Biotechnology (Healthcare), while LRCX operates in Semiconductor Equipment & Materials (Technology). Over the past 10 years, MDGL returned 43.64%/yr vs 46.89%/yr for LRCX. At a 0.24 correlation, their price movements are largely independent.
Performance
MDGL vs. LRCX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, MDGL achieves a -15.37% return, which is significantly lower than LRCX's 96.76% return. Over the past 10 years, MDGL has underperformed LRCX with an annualized return of 43.64%, while LRCX has yielded a comparatively higher 46.89% annualized return.
MDGL
- 1D
- 0.96%
- 1M
- -1.92%
- YTD
- -15.37%
- 6M
- -15.93%
- 1Y
- 76.44%
- 3Y*
- 22.74%
- 5Y*
- 37.28%
- 10Y*
- 43.64%
LRCX
- 1D
- -2.12%
- 1M
- 21.98%
- YTD
- 96.76%
- 6M
- 114.41%
- 1Y
- 299.76%
- 3Y*
- 78.82%
- 5Y*
- 40.19%
- 10Y*
- 46.89%
MDGL vs. LRCX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
MDGL Madrigal Pharmaceuticals, Inc. | -15.37% | 88.72% | 33.36% | -20.28% | 242.52% | -23.77% | 22.02% | -19.17% | 22.80% | 516.04% |
LRCX Lam Research Corporation | 96.76% | 139.16% | -6.84% | 88.63% | -40.72% | 53.66% | 64.18% | 119.33% | -24.40% | 76.21% |
Correlation
The correlation between MDGL and LRCX is 0.11, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.11 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.20 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.23 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.25 |
Correlation (All Time) Calculated using the full available price history since Feb 7, 2007 | 0.24 |
The correlation between MDGL and LRCX shifts across timeframes, from 0.11 (1 year) to 0.25 (10 years), reflecting how their relationship changes across market environments.
Fundamentals
MDGL:
$14.31B
LRCX:
$424.82B
MDGL:
-$12.87
LRCX:
$5.29
MDGL:
10.46
LRCX:
19.68
MDGL:
26.33
LRCX:
40.13
MDGL:
$1.13B
LRCX:
$21.68B
MDGL:
$1.05B
LRCX:
$10.84B
MDGL:
-$287.63M
LRCX:
$6.10B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
MDGL vs. LRCX — Risk / Return Rank
MDGL
LRCX
MDGL vs. LRCX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Madrigal Pharmaceuticals, Inc. (MDGL) and Lam Research Corporation (LRCX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| MDGL | LRCX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -4.37 | ||
| Sortino ratioReturn per unit of downside risk | -2.37 | ||
| Omega ratioGain probability vs. loss probability | 1.31 | 1.65 | -0.34 |
| Calmar ratioReturn relative to maximum drawdown | 2.62 | 15.09 | -12.48 |
| Martin ratioReturn relative to average drawdown | 5.91 | 51.29 | -45.38 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| MDGL | LRCX | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.67 | 6.05 | -4.37 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.28 | 0.88 | -0.60 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.37 | 1.06 | -0.68 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.02 | 0.43 | -0.41 |
Drawdowns
MDGL vs. LRCX - Drawdown Comparison
The maximum MDGL drawdown since its inception was -98.40%, which is greater than LRCX's maximum drawdown of -87.90%. Use the drawdown chart below to compare losses from any high point for MDGL and LRCX.
Loading charts...
Drawdown Indicators
| MDGL | LRCX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.40% | -87.90% | -10.50% |
Max Drawdown (1Y)Largest decline over 1 year | -29.36% | -20.01% | -9.35% |
Max Drawdown (3Y)Largest decline over 3 years | -56.45% | -47.10% | -9.35% |
Max Drawdown (5Y)Largest decline over 5 years | -61.41% | -56.39% | -5.02% |
Max Drawdown (10Y)Largest decline over 10 years | -82.19% | -56.39% | -25.80% |
Current DrawdownCurrent decline from peak | -18.25% | -2.12% | -16.13% |
Average DrawdownAverage peak-to-trough decline | -58.55% | -28.19% | -30.36% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 12.99% | 5.88% | +7.11% |
Volatility
MDGL vs. LRCX - Volatility Comparison
Madrigal Pharmaceuticals, Inc. (MDGL) and Lam Research Corporation (LRCX) have volatilities of 16.08% and 15.57%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| MDGL | LRCX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 16.08% | 15.57% | +0.51% |
Volatility (6M)Calculated over the trailing 6-month period | 31.56% | 40.27% | -8.71% |
Volatility (1Y)Calculated over the trailing 1-year period | 45.96% | 49.95% | -3.99% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 133.42% | 45.94% | +87.48% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 117.50% | 44.58% | +72.92% |
Dividends
MDGL vs. LRCX - Dividend Comparison
MDGL has not paid dividends to shareholders, while LRCX's dividend yield for the trailing twelve months is around 0.30%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
LRCX Lam Research Corporation | 0.30% | 0.57% | 1.19% | 0.95% | 1.53% | 0.78% | 1.04% | 1.54% | 2.79% | 1.01% | 1.28% | 1.36% |
MDGL Madrigal Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
MDGL vs. LRCX - Financials Comparison
This section allows you to compare key financial metrics between Madrigal Pharmaceuticals, Inc. and Lam Research Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
MDGL vs. LRCX - Profitability Comparison
MDGL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Madrigal Pharmaceuticals, Inc. reported a gross profit of 284.49M and revenue of 311.34M. Therefore, the gross margin over that period was 91.4%.
LRCX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Lam Research Corporation reported a gross profit of 2.91B and revenue of 5.84B. Therefore, the gross margin over that period was 49.8%.
MDGL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Madrigal Pharmaceuticals, Inc. reported an operating income of -92.72M and revenue of 311.34M, resulting in an operating margin of -29.8%.
LRCX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Lam Research Corporation reported an operating income of 2.05B and revenue of 5.84B, resulting in an operating margin of 35.0%.
MDGL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Madrigal Pharmaceuticals, Inc. reported a net income of -94.39M and revenue of 311.34M, resulting in a net margin of -30.3%.
LRCX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Lam Research Corporation reported a net income of 1.83B and revenue of 5.84B, resulting in a net margin of 31.3%.
Frequently Asked Questions
MDGL and LRCX have a correlation of 0.11, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
MDGL has higher volatility (16.08%) compared to LRCX (15.57%). In terms of maximum drawdown, MDGL dropped -98.40% vs LRCX's -87.90%.
LRCX currently has the higher Sharpe Ratio (6.05 vs 1.67), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for MDGL and LRCX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer